KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinomaNikolaj Frost, Christian Grohé, Dennis Pultermann et al.|Translational Lung Cancer Research|2021Cited by 60
Management, risk factors and prognostic impact of checkpoint-inhibitor pneumonitis (CIP) in lung cancer – A multicenter observational analysisNikolaj Frost, Jens Kollmeier, Kristina Unger et al.|Lung Cancer|2023Cited by 18
Implementierung der Tabakentwöhnung in den Workflow des Lungenkrebsscreenings in DeutschlandAlexander Rupp, Sebastian Sohrab, Wulf Pankow et al.|Pneumologie|2024Cited by 4